The Journal of Immunology, Vol 152, Issue 5 2324-2332, Copyright © 1994 by American Association of Immunologists

ARTICLES

The role of IL-2 secreted from genetically modified tumor cells in the establishment of antitumor immunity

R Bannerji, CD Arroyo, C Cordon-Cardo and E Gilboa

Although the importance of CD4+ T cells for the induction of an effective CD8+ cytolytic T cell response is well documented, the mechanism by which MHC class II-negative tumor cells recruit CD4+ T help is not well understood. We have previously shown that IL-2 or IFN- gamma gene-modified CMS-5 tumor cells do not grow in syngeneic mice; however, mice which rejected the cytokine-secreting tumor cells develop a protective immune response against a challenge with parental tumor cells. Here we show that rejection of IL-2-secreting CMS-5 cells is not mediated by T cells. However, establishment of a protective immune response against CMS-5 tumor cells requires the presence of both CD4+ and CD8+ T cell subsets during the period of immunization with IL-2- secreting CMS-5 cells as well as during the effector phase. Extensive histologic analysis has failed to detect the presence of T cells at the site of immunization with either IL-2- or IFN-gamma-secreting CMS-5 cells. The main infiltrate at the site of inoculation with IL-2- secreting CMS-5 cells consisted of NK cells that appeared to play a role in their rejection. The predominant infiltrate at the site of inoculation with IFN-gamma-secreting CMS-5 cells consisted of macrophages. These observations argue against a direct role for the intact tumor cell in presenting either T helper or CTL epitopes to the immune system, and support the view that specialized APC are responsible for the in vivo priming of a T cell response against MHC class I-restricted Ag.

This article has been cited by other articles:

				C. Jackaman, C. S. Bundell, B. F. Kinnear, A. M. Smith, P. Filion, D. van Hagen, B. W. S. Robinson, and D. J. Nelson IL-2 Intratumoral Immunotherapy Enhances CD8+ T Cells That Mediate Destruction of Tumor Cells and Tumor-Associated Vasculature: A Novel Mechanism for IL-2 J. Immunol., November 15, 2003; 171(10): 5051 - 5063. [Abstract] [Full Text] [PDF]

				T. S. Griffith, M. Kawakita, J. Tian, J. Ritchey, J. Tartaglia, I. Sehgal, T. C. Thompson, W. Zhao, and T. L. Ratliff Inhibition of Murine Prostate Tumor Growth and Activation of Immunoregulatory Cells With Recombinant Canarypox Viruses J Natl Cancer Inst, July 4, 2001; 93(13): 998 - 1007. [Abstract] [Full Text] [PDF]

				Y. Goldman, A. Peled, and M. Shinitzky Effective Elimination of Lung Metastases Induced by Tumor Cells Treated with Hydrostatic Pressure and N-Acetyl-L-Cysteine Cancer Res., January 1, 2000; 60(2): 350 - 358. [Abstract] [Full Text]

				A. F. Carpentier, L. Chen, F. Maltonti, and J.-Y. Delattre Oligodeoxynucleotides Containing CpG Motifs Can Induce Rejection of a Neuroblastoma in Mice Cancer Res., November 1, 1999; 59(21): 5429 - 5432. [Abstract] [Full Text] [PDF]

				A. Schneeberger, F. Koszik, W. Schmidt, R. Kutil, and G. Stingl The Tumorigenicity of IL-2 Gene-Transfected Murine M-3D Melanoma Cells Is Determined by the Magnitude and Quality of the Host Defense Reaction: NK Cells Play a Major Role J. Immunol., June 1, 1999; 162(11): 6650 - 6657. [Abstract] [Full Text] [PDF]

				R. Zhang, F. H. Straus, and L. J. DeGroot Effective Genetic Therapy of Established Medullary Thyroid Carcinomas with Murine Interleukin-2: Dissemination and Cytotoxicity Studies in a Rat Tumor Model Endocrinology, May 1, 1999; 140(5): 2152 - 2158. [Abstract] [Full Text]

				M. Nagoshi, P. S. Goedegebuure, U. L. Burger, N. Sadanaga, M. P. Chang, and T. J. Eberlein Successful Adoptive Cellular Immunotherapy Is Dependent on Induction of a Host Immune Response Triggered by Cytokine (IFN-{gamma} and Granulocyte/Macrophage Colony-Stimulating Factor) Producing Donor Tumor-Infiltrating Lymphocytes J. Immunol., January 1, 1998; 160(1): 334 - 344. [Abstract] [Full Text] [PDF]

				W. Schmidt, M. Buschle, W. Zauner, H. Kirlappos, K. Mechtler, B. Trska, and M. L. Birnstiel Cell-free tumor antigen peptide-based cancer vaccines PNAS, April 1, 1997; 94(7): 3262 - 3267. [Abstract] [Full Text] [PDF]